Supplementary Online Content

Lipton RB, Pozo-Rosich P, Blumenfeld AM, et al. Rates of response to atogepant for migraine prophylaxis among adults: a secondary analysis of a randomized clinical trial. *JAMA Netw Open*. 2022;5(6):e2215499. doi:10.1001/jamanetworkopen.2022.15499

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Reduction in 100% in 3-Month Average of MMDs (Prespecified Sensitivity Analysis)

			Atogepant		
		Placebo (n = 214)	10 mg QD (n = 214)	30 mg QD (n = 223)	60 mg QD (n = 222)
Original Analysis	**Responders, n (%)**	2 (0.9)	17 (7.9)	11 (4.9)	17 (7.7)
	OR (95% CI vs PBO	–	9.05 (2.06, 39.81)	6.04 (1.32, 27.71)	9.37 (2.13, 41.26)
	***P* value**	–	**.0036**	**.0207**	**.0031**
Sensitivity Analysis[a]	**Responders, n (%)**	2 (0.9)	18 (8.4)	11 (5.0)	20 (9.1)
	OR (95% CI vs PBO	–	9.62 (2.20, 42.10)	5.90 (1.29, 27.01)	11.03 (2.54, 47.94)
	***P* value**	–	**.0026**	**.0223**	**.0014**

Abbreviations: CI, confidence interval; MMD, monthly migraine day; OR, odds ratio; PBO, placebo; QD, once daily.

[a] Includes day 29 to month 1 after removing day 1 and redefining month 2 and month 3 by shifting them by 1 day to ensure a 28-day assessment period.

eTable 2. Reduction in 100% of MMDs by 4-Week Intervals (Prespecified Sensitivity Analysis)

Reduction of 100% in Average of MMDs, Weeks 1–4					
			Atogepant		
		Placebo (n = 214)	**10 mg QD (n = 214)**	**30 mg QD (n = 223)**	**60 mg QD (n = 222)**
Original Analysis	**Responders, n (%)**	8 (3.8)	30 (14.1)	26 (11.7)	42 (19.0)
	OR (95% CI vs PBO)	–	4.21 (1.88, 9.44)	3.63 (1.60, 8.26)	6.41 (2.92, 14.09)
	P value	–	**.0005**	**.0021**	**<.0001**
Sensitivity Analysis[a]	**Responders, n (%)**	7 (3.3)	34 (16.0)	28 (12.6)	44 (20.1)
	OR (95% CI vs PBO)	–	5.62 (2.42, 13.08)	4.55 (1.93, 10.74)	7.81 (3.40, 17.91)
	P value	–	**<.0001**	**.0006**	**<.0001**
Reduction of 100% in Average of MMDs, Weeks 5–8					
			Atogepant		
		Placebo (n = 214)	**10 mg QD (n = 214)**	**30 mg QD (n = 223)**	**60 mg QD (n = 222)**
Original Analysis	**Responders, n (%)**	17 (8.3)	43 (21.9)	39 (18.5)	50 (24.2)
	OR (95% CI vs PBO)	–	3.15 (1.73, 5.74)	2.66 (1.45, 4.89)	3.74 (2.07, 6.75)
	P value	–	**.0002**	**.0016**	**<.0001**
Sensitivity Analysis[a]	**Responders, n (%)**	20 (9.7)	46 (23.4)	43 (20.4)	51 (24.6)
	OR (95% CI vs PBO)	–	2.86 (1.62, 5.03)	2.53 (1.43, 4.48)	3.18 (1.82, 5.57)
	P value	–	**.0003**	**.0014**	**<.0001**
Reduction of 100% in Average of MMDs, Weeks 9–12					
			Atogepant		
		Placebo (n = 214)	**10 mg QD (n = 214)**	**30 mg QD (n = 223)**	**60 mg QD (n = 222)**
Original Analysis	**Responders, n (%)**	22 (11.2)	40 (21.3)	54 (27.1)	54 (27.7)
	OR (95% CI vs PBO)	–	2.27 (1.27, 4.06)	3.29 (1.88, 5.78)	3.10 (1.76, 5.45)
	P value	–	**.0057**	**<.0001**	**<.0001**
Sensitivity Analysis[a]	**Responders, n (%)**	22 (11.2)	40 (21.5)	53 (26.8)	56 (29.2)
	OR (95% CI vs PBO)	–	2.28 (1.27, 4.09)	3.28 (1.86, 5.78)	3.35 (1.90, 5.91)
	P value	–	**.0059**	**<.0001**	**<.0001**

Abbreviations: CI, confidence interval; MMD, monthly migraine day; OR, odds ratio; PBO, placebo; QD, once daily.

[a] Includes day 29 to month 1 after removing day 1 and redefining month 2 and month 3 by shifting them by 1 day to ensure a 28-day assessment period.

eTable 3. Percentage of Participants Reporting Adverse Events (Safety Population)

		Atogepant		
n (%)	**Placebo (n = 222)**	**10 mg QD (n = 221)**	**30 mg QD (n = 228)**	**60 mg QD (n = 231)**
≥1 TEAE	126 (56.8)	117 (52.9)	119 (52.2)	124 (53.7)
≥1 treatment-related TEAE	20 (9.0)	51 (23.1)	34 (14.9)	45 (19.5)
AE leading to discontinuation	6 (2.7)	9 (4.1)	4 (1.8)	6 (2.6)
Treatment-emergent SAE	2 (0.9)	2 (0.9)	0	0
Death	0	0	0	0

Abbreviations: AE, adverse event; QD, once daily; SAE, serious adverse event; TEAE, treatment-emergent adverse event.

eTable 4. Patient Global Impression of Change and Treatment Satisfaction After 12 Weeks of Randomized, Blinded Treatment

		Atogepant		
Responder Criteria, Week 12	**Placebo (n=214)**	**10 mg QD (n=214)**	**30 mg QD (n=223)**	**60 mg QD (n=222)**
PGI-C,[a] n/N	95/206	145/201	153/209	162/213
Percentage	46.1%	72.1%	73.2%	76.1%
OR (95% CI)	–	3.05 (2.01, 4.61)	3.33 (2.20, 5.05)	3.83 (2.52, 5.84)
P value		<.0001	<.0001	<.0001
Satisfaction with study medication,[b] n/N	109/199	146/188	163/203	166/201
Percentage	54.8%	77.7%	80.3%	82.6%
OR (95% CI)	–	2.77 (1.81, 4.24)	3.44 (2.23, 5.30)	3.58 (2.31, 5.54)
P value		<.0001	<.0001	<.0001

Abbreviations: OR, odds ratio; PGI-C, Patient Global Impression of Change; QD, once daily.
[a] Response defined as “much better” or “very much better.”
[b] Response defined as “satisfied” or “extremely satisfied.”